COVID-19|Regulates use of Johnson & Johnson Vaccine.

The COVID-19 pandemic continues to be talked about and continues to expand, now with the new variant that recently appeared in Brazil, which has generated an increase in the number of daily infections, as this strain or new variant is much more aggressive than the one that initially appeared a little more than a year ago, The efforts that the World Health Organization (OMS) and the countries of the world have made to avoid the increase in the number of daily infections have apparently not yielded results, not because the biosecurity measures do not work, but because of the lack of awareness of the people in not complying with these measures.

In addition to these biosecurity measures, there is now a massive vaccination process being carried out in a large part of the world's population at the present time, with the aim of preventing further contagion and deaths due to this deadly virus, This vaccination process that is currently being applied is also causing a lot of discussion because the vaccines that have been released to counteract the attacks of COVID-19 are presenting side effects in the vaccinated population. A few months ago, eight countries of the European Union had restricted the use of the AstraZeneca vaccine, due to the fact that some deaths had been generated by thromboembolism in people who have received doses of this vaccine.

Now it is Johnson & Johnson's turn, as U.S. health authorities have suggested a "Pause" as a precautionary measure in the use of this vaccine while they investigate whether it produces blood clots. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are evaluating the possibility of the existence of six reported cases of rare blood clots in patients who have been vaccinated. These authorities are suggesting a "Pause" until the verification process is completed, their sources reported. To date, about 6.8 million doses of the Johnson & Johnson vaccine have been administered in the U.S. alone.

Johnson & Johnson responded with a statement saying that safety is its number one priority and therefore shares the reports presented by the health authorities, Johnson & Johnson said: "We are aware that thromboembolic events, including thrombocytopenia, have been reported with the use of covid-19 vaccines. At present, a clear causal relationship between these rare events and the Janssen (J&J) vaccine has not been established."

In conclusion, we can infer that even if some specific cases are registered with these vaccines, the population should be calm because the competent organizations are attentive to any situation that may arise once the dose of any vaccine is applied and thus be able to give immediate responses. As in the case of Johnson & Johnson, although the cases have not been made official, they prefer to be cautious and give a "Pause" in the application of this vaccine.